Keli Walbert was appointed Director of Hemab Therapeutics Holdings, Inc. As of November 7, 2026, Hemab Therapeutics Holdings, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 11, 2026 to September 24, 2026, naming 2 appointments and 1 departure (Form 8-K, September 24, 2026).
Hemab Therapeutics Holdings, Inc. named a new Director on Sep 24. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Hemab Therapeutics Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Hemab Therapeutics Holdings, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-11 to 2026-09-24. They name 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Hemab Therapeutics Holdings, Inc. files it.
Also on the record for Hemab Therapeutics Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 10.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Behzad Aghazadeh | 7.06% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Novo Holdings A/S | 9% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by Capital International Investors | 7.7% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by Raymond Debbane | 5.1% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 7.9% of the class | 5%+ stakes | Source |
| August 5, 2026 | Stake report, Schedule 13G, by Sofinnova Crossover II SLP | 5.4% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13D, by AI DEN-MAB LLC | 10.4% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 16.6% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G, by Deep Track Capital, LP | 8.15% of the class | 5%+ stakes | Source |
| May 1, 2026 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| April 30, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
Selling to them or working with them? See who runs Hemab Therapeutics Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Hemab Therapeutics Holdings, Inc. and the records around it.
Hemab Therapeutics Holdings, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), MAPLIGHT THERAPEUTICS, INC. (Jul 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Scribe Therapeutics, Inc. (Jul 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Watch Hemab Therapeutics Holdings, Inc.
Get an email when Hemab Therapeutics Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Hemab Therapeutics Holdings, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Hemab Therapeutics Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Hemab Therapeutics Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-24 | In | Director | 8-K, 2026-09-24 | ||
| 2026-09-24 | In | 8-K, 2026-09-24 | |||
| 2026-05-11 | Out | Director | 8-K, 2026-05-11 |
Who leads Hemab Therapeutics Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Keli Walbert, appointed (filed 2026-09-24).
New leaders reset buying decisions — get the Full Report on Hemab Therapeutics Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Hemab Therapeutics Holdings, Inc., with the record behind each one.
Find candidates like Director at Hemab Therapeutics Holdings, Inc.Every change, in the filing's words
Appointed: Keli Walbert, Director
On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Hemab Therapeutics Holdings, Inc. (the "Company"), the Board elected Keli Walbert to serve as a member of the Board, effective immediately.
Appointed: Keli Walbert
The Board also elected Ms. Walbert to serve as a member of the Audit Committee of the Board (the "Audit Committee").
- Ms. Walbert will serve as a Class I director with a term expiring at the 2027 annual meeting of stockholders and thereafter until her successor has been duly elected and qualified or until her earlier death, resignation or removal.
- In accordance with the policy, effective September 24, 2026 (the "Grant Date"), Ms. Walbert will be granted an option to purchase 36,000 shares of the Company's common stock at an exercise price equal to the closing price of the Company's common stock on the Grant Date, which option will vest in equal monthly installments from the Grant Date until the third anniversary of the Grant Date, subject to Ms. Walbert's continued service.
- In the event of a change in control of the Company, the vesting schedule of the option will accelerate in full.
- In addition, Ms. Walbert will receive annual cash compensation of $40,000 as a member of the Board, additional annual cash compensation of $10,000 as a member of the Audit Committee, annual equity grants in accordance with the non-employee director compensation policy and reimbursement for reasonable travel and out-of-pocket expenses incurred in connection with attending Board and committee meetings.
Departing: Laura Tadvalkar, Director
On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the "Company") of her decision to resign as a member of the Company's board of directors (the "Board"), effective immediately.
- Dr. Tadvalkar's resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.
Tools for this story
Each opens in a new tab, filled in for Hemab Therapeutics Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.